The Gastric Cancer Drugs Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Gastric Cancer Drugs Market?
The market size of the gastric cancer drugs has seen speedy growth recently. The market is predicted to expand from $4.43 billion in 2024 to $5.01 billion in 2025, with a compound annual growth rate (CAGR) of 12.9%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Gastric Cancer Drugs Industry?
The Gastric Cancer Drugs Global Market Report 2025 forecasts the market size to reach $7.6 billion by 2029, growing at a compound annual growth rate (CAGR) of 11.0%.
Download Your Free Sample of the 2025 Gastric Cancer Drugs Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Gastric Cancer Drugs Market?
The key drivers in the gastric cancer drugs market are:
• Rising incidence rate of gastric cancer
• Strong pipeline of gastric cancer drugs
• Increase in acquisitions and partnerships in the pharmaceutical sector
• Revised FDA regulations promoting the development of biologics drugs
Global Market Segmentation: Identifying Major Gastric Cancer Drugs Industry Segments
The gastric cancer drugs market covered in this report is segmented –
1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers
Pre-order the 2025 Gastric Cancer Drugs Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Gastric Cancer Drugs Market?
The key trends in the gastric cancer drugs market are:
• Strategic collaborations and partnerships are emerging trends, with companies seeking to broaden their product portfolios.
• There is an increased emphasis on enhancing the pipeline studies for the development of gastric cancer drugs.
• Investment in AI solutions to reduce R&D costs is shaping the future of the market.
• Utilization of advanced technologies like CRISPR-cas9 in new drug development is a notable future trend.
Who Are the Top Competitors & Leading Players in the Gastric Cancer Drugs Market?
Major companies in the gastric cancer drugs market are:
• F. Hoffmann-La Roche
• Eli Lilly and Company
• Otsuka Pharmaceutical
• Jiangsu HengRui Medicine
• Biocon
• Sanofi
• PV Pharma Healthcare (India)
• Roche India
• Novartis Oncology
• Arlak Biotech (India)
• Healthkind labs Pvt. Ltd.
• SwisscheM Healthcare Pvt.Ltd
• Apikos Pharma
• Kolaz biotech.
• CStone Pharma (China)
• CARsgen Therapeutics (China)
• JW Therapeutics (China)
• BeiGene(China)
• Takeda Pharmaceuticals (Japan)
• Astellas Pharma Inc (Japan)
• Daiichi Pharmaceutical and Sankyo (Japan)
• AQVIDA GmbH
• AstraZeneca plc
• GlaxoSmithKline plc
• Veropharm
• Biocad
• Bristol-Myers Squibb
• Celon Pharma
• Celltrion Inc.
• Imugene Limited
• Merck & Co. Inc.
• Pfizer Inc.
• Sandoz AG (A Novartis Division)
• Eurofarma Laboratórios S.A.
• TUTEUR ArgentinaPierre Fabre Group
• Celnova Pharma
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO)
• Gulf Pharmaceutical Industries (Julphar)
• Abbott Laboratories
• Mylan Laboratories
• Gilead Sciences
• BMS
• Ascedis Health
Regional Dominance: Which Area Leads the Global Template Market?
North America was the largest region in the gastric cancer drugs market in 2024
